Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2023

Open Access 01-12-2023 | Checkpoint Inhibitors | Review

Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment

Authors: Zhifei Gao, Yifeng Bai, Anqi Lin, Aimin Jiang, Chaozheng Zhou, Quan Cheng, Zaoqu Liu, Xin Chen, Jian Zhang, Peng Luo

Published in: Molecular Cancer | Issue 1/2023

Login to get access

Abstract

As a nontraditional T-cell subgroup, γδT cells have gained popularity in the field of immunotherapy in recent years. They have extraordinary antitumor potential and prospects for clinical application. Immune checkpoint inhibitors (ICIs), which are efficacious in tumor patients, have become pioneer drugs in the field of tumor immunotherapy since they were incorporated into clinical practice. In addition, γδT cells that have infiltrated into tumor tissues are found to be in a state of exhaustion or anergy, and there is upregulation of many immune checkpoints (ICs) on their surface, suggesting that γδT cells have a similar ability to respond to ICIs as traditional effector T cells. Studies have shown that targeting ICs can reverse the dysfunctional state of γδT cells in the tumor microenvironment (TME) and exert antitumor effects by improving γδT-cell proliferation and activation and enhancing cytotoxicity. Clarification of the functional state of γδT cells in the TME and the mechanisms underlying their interaction with ICs will solidify ICIs combined with γδT cells as a good treatment option.
Appendix
Available only for authorised users
Literature
1.
Zakeri N, Hall A, Swadling L, Pallett LJ, Schmidt NM, Diniz MO, et al. Characterisation and induction of tissue-resident gamma delta T-cells to target hepatocellular carcinoma. Nat Commun. 2022;13:1372.PubMedPubMedCentralCrossRef
2.
Wu Y, Biswas D, Usaite I, Angelova M, Boeing S, Karasaki T, et al. A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer. Nat Cancer. 2022;3:696–709.PubMedPubMedCentralCrossRef
3.
Mikulak J, Oriolo F, Bruni E, Roberto A, Colombo FS, Villa A, et al. NKp46-expressing human gut-resident intraepithelial Vδ1 T cell subpopulation exhibits high antitumor activity against colorectal cancer. JCI Insight. 2019;4:125884.PubMedCrossRef
4.
5.
Bruni E, Cimino MM, Donadon M, Carriero R, Terzoli S, Piazza R, et al. Intrahepatic CD69+Vδ1 T cells re-circulate in the blood of patients with metastatic colorectal cancer and limit tumor progression. J Immunother Cancer. 2022;10:e004579.PubMedPubMedCentralCrossRef
6.
Hayday AC. Gammadelta T cells and the lymphoid stress-surveillance response. Immunity. 2009;31:184–96.PubMedCrossRef
7.
8.
9.
Sebestyen Z, Prinz I, Déchanet-Merville J, Silva-Santos B, Kuball J. Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies. Nat Rev Drug Discov. 2020;19:169–84.PubMedCrossRef
10.
Conejo-Garcia JR, Innamarato P. γδ T cells share the spotlight in cancer. Nat Cancer. 2022;3:657–8.PubMedCrossRef
11.
Xu Y, Xiang Z, Alnaggar M, Kouakanou L, Li J, He J, et al. Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer. Cell Mol Immunol. 2021;18:427–39.PubMedCrossRef
12.
13.
14.
15.
Park JH, Kim H-J, Kim CW, Kim HC, Jung Y, Lee H-S, et al. Tumor hypoxia represses γδ T cell-mediated antitumor immunity against brain tumors. Nat Immunol. 2021;22:336–46.PubMedCrossRef
16.
Chabab G, Barjon C, Bonnefoy N, Lafont V. Pro-tumor γδ T cells in human Cancer: polarization, mechanisms of action, and implications for therapy. Front Immunol. 2020;11:2186.PubMedPubMedCentralCrossRef
17.
Andreu-Ballester JC, Galindo-Regal L, Hidalgo-Coloma J, Cuéllar C, García-Ballesteros C, Hurtado C, et al. Differences in circulating γδ T cells in patients with primary colon cancer and relation with prognostic factors. PLoS One. 2020;15:e0243545.PubMedPubMedCentralCrossRef
18.
Janssen A, Villacorta Hidalgo J, Beringer DX, van Dooremalen S, Fernando F, van Diest E, et al. γδ T-cell receptors derived from breast Cancer-infiltrating T lymphocytes mediate antitumor reactivity. Cancer Immunol Res. 2020;8:530–43.PubMedCrossRef
19.
Ou L, Wang H, Huang H, Zhou Z, Lin Q, Guo Y, et al. Preclinical platforms to study therapeutic efficacy of human γδ T cells. Clin Transl Med. 2022;12:e814.PubMedPubMedCentralCrossRef
20.
21.
Nakamura K, Smyth MJ, Martinet L. Cancer immunoediting and immune dysregulation in multiple myeloma. Blood. 2020;136:2731–40.PubMedCrossRef
22.
23.
24.
Jhunjhunwala S, Hammer C, Delamarre L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat Rev Cancer. 2021;21:298–312.PubMedCrossRef
25.
Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, Loftin SK, et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol. 2003;4:670–9.PubMedCrossRef
26.
27.
Bagchi S, Yuan R, Engleman EG. Immune Checkpoint inhibitors for the treatment of Cancer: clinical impact and mechanisms of response and Resistance. Annu Rev Pathol. 2021;16:223–49.PubMedCrossRef
28.
de Miguel M, Calvo E. Clinical challenges of Immune Checkpoint inhibitors. Cancer Cell. 2020;38:326–33.PubMedCrossRef
29.
30.
31.
32.
33.
Reis BS, Darcy PW, Khan IZ, Moon CS, Kornberg AE, Schneider VS, et al. TCR-Vγδ usage distinguishes protumor from antitumor intestinal γδ T cell subsets. Science. 2022;377:276–84.PubMedPubMedCentralCrossRef
34.
35.
Bottino C, Tambussi G, Ferrini S, Ciccone E, Varese P, Mingari MC, et al. Two subsets of human T lymphocytes expressing gamma/delta antigen receptor are identifiable by monoclonal antibodies directed to two distinct molecular forms of the receptor. J Exp Med. 1988;168:491–505.PubMedCrossRef
36.
Dang W, Pin W, Qiu F, Wei Q, Huang J. Human γδT-cell subsets and their involvement in tumor immunity. Cell Mol Immunol. 2017;14:245–53.CrossRef
37.
O’Brien RL, Born WK. Two functionally distinct subsets of IL-17 producing γδ T cells. Immunol Rev. 2020;298:10–24.PubMedCrossRef
38.
Casetti R, Agrati C, Wallace M, Sacchi A, Martini F, Martino A, et al. Cutting edge: TGF-beta1 and IL-15 induce FOXP3+ gammadelta regulatory T cells in the presence of antigen stimulation. J Immunol. 2009;183:3574–7.PubMedCrossRef
39.
Peters C, Meyer A, Kouakanou L, Feder J, Schricker T, Lettau M, et al. TGF-β enhances the cytotoxic activity of Vδ2 T cells. Oncoimmunology. 2019;8:e1522471.PubMedCrossRef
40.
Lo Presti E, Toia F, Oieni S, Buccheri S, Turdo A, Mangiapane LR, et al. Squamous Cell tumors recruit γδ T cells producing either IL17 or IFNγ depending on the Tumor stage. Cancer Immunol Res. 2017;5:397–407.PubMedCrossRef
41.
42.
43.
Lo Presti E, Dieli F, Fourniè JJ, Meraviglia S. Deciphering human γδ T cell response in cancer: lessons from tumor-infiltrating γδ T cells. Immunol Rev. 2020;298:153–64.PubMedCrossRef
44.
Wu Y, Kyle-Cezar F, Woolf RT, Naceur-Lombardelli C, Owen J, Biswas D, et al. An innate-like Vδ1+ γδ T cell compartment in the human breast is associated with remission in triple-negative breast cancer. Sci Transl Med. 2019;11:eaax9364.PubMedPubMedCentralCrossRef
45.
Lu H, Dai W, Guo J, Wang D, Wen S, Yang L, et al. High abundance of Intratumoral γδ T cells favors a better prognosis in head and neck squamous Cell carcinoma: a Bioinformatic analysis. Front Immunol. 2020;11:573920.PubMedPubMedCentralCrossRef
46.
Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21:938–45.PubMedPubMedCentralCrossRef
47.
Lee M, Park C, Woo J, Kim J, Kho I, Nam D-H, et al. Preferential infiltration of unique Vγ9Jγ2-Vδ2 T cells into glioblastoma Multiforme. Front Immunol. 2019;10:555.PubMedPubMedCentralCrossRef
48.
Bryant NL, Gillespie GY, Lopez RD, Markert JM, Cloud GA, Langford CP, et al. Preclinical evaluation of ex vivo expanded/activated γδ T cells for immunotherapy of glioblastoma multiforme. J Neuro-Oncol. 2011;101:179–88.CrossRef
49.
Chan KF, Duarte JDG, Ostrouska S, Behren A. γδ T cells in the Tumor Microenvironment-interactions with other Immune cells. Front Immunol. 2022;13:894315.PubMedPubMedCentralCrossRef
50.
Girard P, Ponsard B, Charles J, Chaperot L, Aspord C. Potent bidirectional cross-talk between Plasmacytoid dendritic cells and γδT cells through BTN3A, type I/II IFNs and Immune checkpoints. Front Immunol. 2020;11:861.PubMedPubMedCentralCrossRef
51.
Castella B, Foglietta M, Sciancalepore P, Rigoni M, Coscia M, Griggio V, et al. Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma. Oncoimmunology. 2015;4:e1047580.PubMedPubMedCentralCrossRef
52.
53.
Horner AA, Jabara H, Ramesh N, Geha RS. Gamma/delta T lymphocytes express CD40 ligand and induce isotype switching in B lymphocytes. J Exp Med. 1995;181:1239–44.PubMedCrossRef
54.
55.
Ullrich L, Lueder Y, Juergens A-L, Wilharm A, Barros-Martins J, Bubke A, et al. IL-4-producing Vγ1+/Vδ6+ γδ T cells sustain germinal center reactions in Peyer’s patches of mice. Front Immunol. 2021;12:729607.PubMedPubMedCentralCrossRef
56.
Yang Y, Li L, Yuan L, Zhou X, Duan J, Xiao H, et al. A structural change in Butyrophilin upon Phosphoantigen binding underlies Phosphoantigen-Mediated Vγ9Vδ2 T Cell activation. Immunity. 2019;50:1043–1053.e5.PubMedCrossRef
57.
Siyi G, Borowska MT, Boughter CT, Adams EJ. Butyrophilin3A proteins and Vγ9Vδ2 T cell activation. Semin Cell Dev Biol. 2018;84:65–74.CrossRef
58.
Morita CT, Beckman EM, Bukowski JF, Tanaka Y, Band H, Bloom BR, et al. Direct presentation of nonpeptide prenyl pyrophosphate antigens to human gamma delta T cells. Immunity. 1995;3:495–507.PubMedCrossRef
59.
60.
61.
Djaoud Z, Parham P. HLAs, TCRs, and KIRs, a triumvirate of human Cell-Mediated Immunity. Annu Rev Biochem. 2020;89:717–39.PubMedCrossRef
62.
Boutin L, Scotet E. Towards deciphering the hidden mechanisms that contribute to the antigenic activation process of human Vγ9Vδ2 T cells. Front Immunol. 2018;9:828.PubMedPubMedCentralCrossRef
63.
Rigau M, Uldrich AP, Behren A. Targeting butyrophilins for cancer immunotherapy. Trends Immunol. 2021;42:670–80.PubMedCrossRef
64.
Sandstrom A, Peigné C-M, Léger A, Crooks JE, Konczak F, Gesnel M-C, et al. The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human Vγ9Vδ2 T cells. Immunity. 2014;40:490–500.PubMedPubMedCentralCrossRef
65.
Benyamine A, Loncle C, Foucher E, Blazquez J-L, Castanier C, Chrétien A-S, et al. BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC). Oncoimmunology. 2017;7:e1372080.PubMedPubMedCentralCrossRef
66.
67.
Rhodes DA, Chen H-C, Williamson JC, Hill A, Yuan J, Smith S, et al. Regulation of human γδ T cells by BTN3A1 protein stability and ATP-binding cassette transporters. Front Immunol. 2018;9:662.PubMedPubMedCentralCrossRef
68.
69.
Laplagne C, Ligat L, Foote J, Lopez F, Fournié J-J, Laurent C, et al. Self-activation of Vγ9Vδ2 T cells by exogenous phosphoantigens involves TCR and butyrophilins. Cell Mol Immunol. 2021;18:1861–70.PubMedPubMedCentralCrossRef
70.
71.
Miyashita M, Shimizu T, Ashihara E, Ukimura O. Strategies to improve the antitumor effect of γδ T Cell immunotherapy for clinical application. Int J Mol Sci. 2021;22:8910.PubMedPubMedCentralCrossRef
72.
73.
Mao Y, Yin S, Zhang J, Hu Y, Huang B, Cui L, et al. A new effect of IL-4 on human γδ T cells: promoting regulatory Vδ1 T cells via IL-10 production and inhibiting function of Vδ2 T cells. Cell Mol Immunol. 2016;13:217–28.PubMedCrossRef
74.
75.
Sabbione F, Gabelloni ML, Ernst G, Gori MS, Salamone G, Oleastro M, et al. Neutrophils suppress γδ T-cell function. Eur J Immunol. 2014;44:819–30.PubMedCrossRef
76.
Kersten K, Coffelt SB, Hoogstraat M, Verstegen NJM, Vrijland K, Ciampricotti M, et al. Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1β in tumor-associated macrophages. Oncoimmunology. 2017;6:e1334744.PubMedPubMedCentralCrossRef
77.
Zuberbuehler MK, Parker ME, Wheaton JD, Espinosa JR, Salzler HR, Park E, et al. The transcription factor c-Maf is essential for the commitment of IL-17-producing γδ T cells. Nat Immunol. 2019;20:73–85.PubMedCrossRef
78.
Chen S, Fan J, Zhang M, Qin L, Dominguez D, Long A, et al. CD73 expression on effector T cells sustained by TGF-β facilitates tumor resistance to anti-4-1BB/CD137 therapy. Nat Commun. 2019;10:150.PubMedPubMedCentralCrossRef
79.
80.
Otsuka A, Hanakawa S, Miyachi Y, Kabashima K. CD39: a new surface marker of mouse regulatory γδ T cells. J Allergy Clin Immunol. 2013;132:1448–51.PubMedCrossRef
81.
82.
Deng W-W, Li Y-C, Ma S-R, Mao L, Yu G-T, Bu L-L, et al. Specific blockade CD73 alters the “exhausted” phenotype of T cells in head and neck squamous cell carcinoma. Int J Cancer. 2018;143:1494–504.PubMedCrossRef
83.
Gallerano D, Ciminati S, Grimaldi A, Piconese S, Cammarata I, Focaccetti C, et al. Genetically driven CD39 expression shapes human tumor-infiltrating CD8+ T-cell functions. Int J Cancer. 2020;147:2597–610.PubMedCrossRef
84.
Coffelt SB, Kersten K, Doornebal CW, Weiden J, Vrijland K, Hau C-S, et al. IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis. Nature. 2015;522:345–8.PubMedPubMedCentralCrossRef
85.
Jin C, Lagoudas GK, Zhao C, Bullman S, Bhutkar A, Hu B, et al. Commensal microbiota promote lung cancer development via γδ T cells. Cell. 2019;176:998–1013.e16.PubMedPubMedCentralCrossRef
86.
87.
Gruenbacher G, Gander H, Rahm A, Idzko M, Nussbaumer O, Thurnher M. Ecto-ATPase CD39 inactivates isoprenoid-derived Vγ9Vδ2 T Cell Phosphoantigens. Cell Rep. 2016;16:444–56.PubMedCrossRef
88.
Jandke A, Melandri D, Monin L, Ushakov DS, Laing AG, Vantourout P, et al. Butyrophilin-like proteins display combinatorial diversity in selecting and maintaining signature intraepithelial γδ T cell compartments. Nat Commun. 2020;11:3769.PubMedPubMedCentralCrossRef
89.
Willcox CR, Vantourout P, Salim M, Zlatareva I, Melandri D, Zanardo L, et al. Butyrophilin-like 3 directly binds a human Vγ4+ T Cell receptor using a modality distinct from clonally-restricted antigen. Immunity. 2019;51:813–825.e4.PubMedPubMedCentralCrossRef
90.
Castella B, Melaccio A, Foglietta M, Riganti C, Massaia M. Vγ9Vδ2 T cells as strategic weapons to improve the potency of Immune Checkpoint blockade and Immune interventions in human myeloma. Front Oncol. 2018;8:508.PubMedPubMedCentralCrossRef
91.
Hsu H, Boudova S, Mvula G, Divala TH, Mungwira RG, Harman C, et al. Prolonged PD1 expression on neonatal Vδ2 lymphocytes dampens Proinflammatory responses: role of epigenetic regulation. J Immunol. 2016;197:1884–92.PubMedCrossRef
92.
93.
Yi H, Chen D, Hong M, Liu J, Li Y, Hao J, et al. Apoptosis, Pyroptosis, and Ferroptosis conspiringly induce immunosuppressive hepatocellular carcinoma Microenvironment and γδ T-Cell imbalance. Front Immunol. 2022;13:845974.CrossRef
94.
Macek JZ. Gamma delta T cells in hepatocellular carcinoma: sunrise of new therapy based on Vδ2 T cells? Clin Transl Med. 2022;12:e834.
95.
96.
Jin Z, Lan T, Zhao Y, Jinxia D, Chen J, Lai J, et al. Higher TIGIT+CD226- γδ T cells in patients with acute myeloid leukemia. Immunol Investig. 2022;51:40–50.CrossRef
97.
Wu K, Feng J, Xiu Y, Li Z, Lin Z, Zhao H, et al. Vδ2 T cell subsets, defined by PD-1 and TIM-3 expression, present varied cytokine responses in acute myeloid leukemia patients. Int Immunopharmacol. 2020;80:106122.PubMedCrossRef
98.
Catafal-Tardos E, Baglioni MV, Bekiaris V. Inhibiting the unconventionals: importance of immune checkpoint receptors in γδ T, MAIT, and NKT cells. Cancers. 2021;13:4647.PubMedPubMedCentralCrossRef
99.
Gorgulho J, Roderburg C, Heymann F, Schulze-Hagen M, Beier F, Vucur M, et al. Serum levels of soluble B and T lymphocyte attenuator predict overall survival in patients undergoing immune checkpoint inhibitor therapy for solid malignancies. Int J Cancer. 2021;149:1189–98.PubMedCrossRef
100.
Zhan Y, Zheng L, Liu J, Dongzhi H, Wang J, Liu K, et al. PLA2G4A promotes right-sided colorectal cancer progression by inducing CD39+γδ Treg polarization. JCI Insight. 2021;6:148028.CrossRef
101.
102.
López-Botet M, Bellón T, Llano M, Navarro F, García P, de Miguel M. Paired inhibitory and triggering NK cell receptors for HLA class I molecules. Hum Immunol. 2000;61:7–17.PubMedCrossRef
103.
104.
Trichet V, Benezech C, Dousset C, Gesnel M-C, Bonneville M, Breathnach R. Complex interplay of activating and inhibitory signals received by Vgamma9Vdelta2 T cells revealed by target cell beta2-microglobulin knockdown. J Immunol. 2006;177:6129–36.PubMedCrossRef
105.
Harly C, Peyrat M-A, Netzer S, Déchanet-Merville J, Bonneville M, Scotet E. Up-regulation of cytolytic functions of human Vδ2-γ T lymphocytes through engagement of ILT2 expressed by tumor target cells. Blood. 2011;117:2864–73.PubMedCrossRef
106.
Lesport E, Baudhuin J, Sousa S, LeMaoult J, Zamborlini A, Rouas-Freiss N, et al. Inhibition of human gamma delta [corrected] T-cell antitumoral activity through HLA-G: implications for immunotherapy of cancer. Cell Mol Life Sci. 2011;68:3385–99.PubMedCrossRef
107.
108.
109.
Angelini DF, Zambello R, Galandrini R, Diamantini A, Placido R, Micucci F, et al. NKG2A inhibits NKG2C effector functions of γδ T cells: implications in health and disease. J Leukoc Biol. 2011;89:75–84.PubMedCrossRef
110.
Cazzetta V, Bruni E, Terzoli S, Carenza C, Franzese S, Piazza R, et al. NKG2A expression identifies a subset of human Vδ2 T cells exerting the highest antitumor effector functions. Cell Rep. 2021;37:109871.PubMedCrossRef
111.
Borst L, Sluijter M, Sturm G, Charoentong P, Santegoets SJ, van Gulijk M, et al. NKG2A is a late immune checkpoint on CD8 T cells and marks repeated stimulation and cell division. Int J Cancer. 2022;150:688–704.PubMedCrossRef
112.
Magalhães A, Duarte HO, Reis CA. Aberrant glycosylation in Cancer: a Novel molecular mechanism controlling metastasis. Cancer Cell. 2017;31:733–5.PubMedCrossRef
113.
Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015;15:540–55.PubMedCrossRef
114.
Zhang Z, Yang C, Li L, Zhu Y, Su K, Zhai L, et al. “γδT Cell-IL17A-neutrophil” Axis drives immunosuppression and confers breast Cancer Resistance to high-dose anti-VEGFR2 therapy. Front Immunol. 2021;12:699478.PubMedPubMedCentralCrossRef
115.
van de Wall S, Santegoets KCM, van Houtum EJH, Büll C, Adema GJ. Sialoglycans and Siglecs can shape the Tumor Immune Microenvironment. Trends Immunol. 2020;41:274–85.PubMedCrossRef
116.
117.
Cagnoni AJ, Giribaldi ML, Blidner AG, Cutine AM, Gatto SG, Morales RM, et al. Galectin-1 fosters an immunosuppressive microenvironment in colorectal cancer by reprogramming CD8+ regulatory T cells. P Natl Acad Sci USA. 2021;118:e2102950118.CrossRef
118.
Yang R, Sun L, Li C-F, Wang Y-H, Yao J, Li H, et al. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nat Commun. 2021;12:832.PubMedPubMedCentralCrossRef
119.
120.
121.
122.
Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017;545:495–9.PubMedPubMedCentralCrossRef
123.
Garnier J, Turrini O, Chretien A-S, Olive D. Local ablative therapy associated with immunotherapy in locally advanced pancreatic cancer: a solution to overcome the double trouble?-a comprehensive review. J Clin Med. 2022;11:1948.PubMedPubMedCentralCrossRef
124.
Daley D, Zambirinis CP, Seifert L, Akkad N, Mohan N, Werba G, et al. γδ T cells support pancreatic oncogenesis by restraining αβ T Cell activation. Cell. 2016;166:1485–1499.e15.PubMedPubMedCentralCrossRef
125.
Lopes N, Silva-Santos B. Functional and metabolic dichotomy of murine γδ T cell subsets in cancer immunity. Eur J Immunol. 2021;51:17–26.PubMedCrossRef
126.
Yanyun D, Qianwen Peng D, Cheng TP, Sun W, Wang H, et al. Cancer cell-expressed BTNL2 facilitates tumour immune escape via engagement with IL-17A-producing γδ T cells. Nat Commun. 2022;13:231.CrossRef
127.
128.
129.
130.
131.
Aotsuka A, Matsumoto Y, Arimoto T, Kawata A, Ogishima J, Taguchi A, et al. Interleukin-17 is associated with expression of programmed cell death 1 ligand 1 in ovarian carcinoma. Cancer Sci. 2019;110:3068–78.PubMedPubMedCentralCrossRef
132.
133.
Zeng J, Ning Z, Wang Y, Xiong H. Implications of CD39 in immune-related diseases. Int Immunopharmacol. 2020;89:107055.PubMedCrossRef
134.
Willingham SB, Ho PY, Hotson A, Hill C, Piccione EC, Hsieh J, et al. A2AR antagonism with CPI-444 induces antitumor responses and augments efficacy to anti-PD-(L)1 and anti-CTLA-4 in preclinical models. Cancer Immunol Res. 2018;6:1136–49.PubMedCrossRef
135.
Chabab G, Barjon C, Abdellaoui N, Salvador-Prince L, Dejou C, Michaud H-A, et al. Identification of a regulatory Vδ1 gamma delta T cell subpopulation expressing CD73 in human breast cancer. J Leukoc Biol. 2020;107:1057–67.PubMedCrossRef
136.
Ni C, Fang Q-Q, Chen W-Z, Jiang J-X, Jiang Z, Ye J, et al. Breast cancer-derived exosomes transmit lncRNA SNHG16 to induce CD73+γδ1 Treg cells. Signal Transduct Tar. 2020;5:41.CrossRef
137.
Guoming H, Pin W, Cheng P, Zhang Z, Wang Z, Xiuyan Y, et al. Tumor-infiltrating CD39+γδTregs are novel immunosuppressive T cells in human colorectal cancer. Oncoimmunology. 2017;6:e1277305.CrossRef
138.
Weimer P, Wellbrock J, Sturmheit T, Oliveira-Ferrer L, Ding Y, Menzel S, et al. Tissue-specific expression of TIGIT, PD-1, TIM-3, and CD39 by γδ T cells in ovarian Cancer. Cells-Basel. 2022;11:964.CrossRef
139.
140.
141.
142.
143.
144.
Wang Y, Zhao N, Zhang X, Li Z, Liang Z, Yang J, et al. Bibliometrics analysis of Butyrophilins as Immune regulators [1992-2019] and implications for Cancer prognosis. Front Immunol. 2020;11:1187.PubMedPubMedCentralCrossRef
145.
He D, Qin Z, Liu Z, Ji X, Gao J, Guo H, et al. Comprehensive analysis of the prognostic value and Immune infiltration of Butyrophilin subfamily 2/3 (BTN2/3) members in Pan-glioma. Front Oncol. 2022;12:816760.PubMedPubMedCentralCrossRef
146.
Blazquez J-L, Benyamine A, Pasero C, Olive D. New insights into the regulation of γδ T cells by BTN3A and other BTN/BTNL in Tumor Immunity. Front Immunol. 2018;9:1601.PubMedPubMedCentralCrossRef
147.
Bian B, Fanale D, Dusetti N, Roque J, Pastor S, Chretien A-S, et al. Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma. Oncoimmunology. 2019;8:e1561120.PubMedPubMedCentralCrossRef
148.
Cai P, Lu Z, Wu J, Qin X, Wang Z, Zhang Z, et al. BTN3A2 serves as a prognostic marker and favors immune infiltration in triple-negative breast cancer. J Cell Biochem. 2020;121:2643–54.PubMedCrossRef
149.
Incorvaia L, Fanale D, Badalamenti G, Porta C, Olive D, De Luca I, et al. Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions. Oncoimmunology. 2020;9:1832348.PubMedPubMedCentralCrossRef
150.
Billon E, Chanez B, Rochigneux P, Albiges L, Vicier C, Pignot G, et al. Soluble BTN2A1 Is a potential prognosis biomarker in pre-treated advanced renal Cell carcinoma. Front Immunol. 2021;12:670827.PubMedPubMedCentralCrossRef
151.
Fanale D, Incorvaia L, Badalamenti G, De Luca I, Algeri L, Bonasera A, et al. Prognostic role of plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in patients affected by metastatic gastrointestinal stromal tumors: can Immune checkpoints act as a sentinel for short-term survival? Cancers. 2021;13:2118.PubMedPubMedCentralCrossRef
152.
153.
154.
Harly C, Guillaume Y, Nedellec S, Peigné C-M, Mönkkönen H, Mönkkönen J, et al. Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset. Blood. 2012;120:2269–79.PubMedPubMedCentralCrossRef
155.
Starick L, Riano F, Karunakaran MM, Kunzmann V, Li J, Kreiss M, et al. Butyrophilin 3A (BTN3A, CD277)-specific antibody 20.1 differentially activates Vγ9Vδ2 TCR clonotypes and interferes with phosphoantigen activation. Eur J Immunol. 2017;47:982–92.PubMedCrossRef
156.
De Gassart A, Le K-S, Brune P, Agaugué S, Sims J, Goubard A, et al. Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T cell-mediated antitumor immune response. Sci Transl Med. 2021;13:eabj0835.PubMedCrossRef
157.
Yamashiro H, Yoshizaki S, Tadaki T, Egawa K, Seo N. Stimulation of human butyrophilin 3 molecules results in negative regulation of cellular immunity. J Leukoc Biol. 2010;88:757–67.PubMedCrossRef
158.
159.
Cano CE, Pasero C, De Gassart A, Kerneur C, Gabriac M, Fullana M, et al. BTN2A1, an immune checkpoint targeting Vγ9Vδ2 T cell cytotoxicity against malignant cells. Cell Rep. 2021;36:109359.PubMedCrossRef
160.
Girard P, Sosa Cuevas E, Ponsard B, Mouret S, Gil H, Col E, et al. Dysfunctional BTN3A together with deregulated immune checkpoints and type I/II IFN dictate defective interplay between pDCs and γδ T cells in melanoma patients, which impacts clinical outcomes. Clin Transl Immunol. 2021;10:e1329.CrossRef
161.
Gu S, Sachleben JR, Boughter CT, Nawrocka WI, Borowska MT, Tarrasch JT, et al. Phosphoantigen-induced conformational change of butyrophilin 3A1 (BTN3A1) and its implication on Vγ9Vδ2 T cell activation. P Natl Acad Sci USA. 2017;114:E7311–20.CrossRef
162.
Karunakaran MM, Willcox CR, Salim M, Paletta D, Fichtner AS, Noll A, et al. Butyrophilin-2A1 directly binds germline-encoded regions of the Vγ9Vδ2 TCR and Is essential for Phosphoantigen sensing. Immunity. 2020;52:487–498.e6.PubMedPubMedCentralCrossRef
163.
164.
Hsiao C-HC, Nguyen K, Jin Y, Vinogradova O, Wiemer AJ. Ligand-induced interactions between butyrophilin 2A1 and 3A1 internal domains in the HMBPP receptor complex. Cell. Chem Biol. 2022;29:985–995.e5.
165.
166.
Vyborova A, Beringer DX, Fasci D, Karaiskaki F, van Diest E, Kramer L, et al. γ9δ2T cell diversity and the receptor interface with tumor cells. J Clin Invest. 2020;130:4637–51.PubMedPubMedCentralCrossRef
167.
168.
Huimin L, Shi T, Wang M, Li X, Yanzheng G, Zhang X, et al. B7-H3 inhibits the IFN-γ-dependent cytotoxicity of Vγ9Vδ2 T cells against colon cancer cells. Oncoimmunology. 2020;9:1748991.CrossRef
169.
Barjon C, Michaud H-A, Fages A, Dejou C, Zampieri A, They L, et al. IL-21 promotes the development of a CD73-positive Vγ9Vδ2 T cell regulatory population. Oncoimmunology. 2017;7:e1379642.PubMedPubMedCentralCrossRef
170.
Guo Q, Zhao P, Zhang Z, Zhang J, Zhang Z, Hua Y, et al. TIM-3 blockade combined with bispecific antibody MT110 enhances the anti-tumor effect of γδ T cells. Cancer Immunol Immunother. 2020;69:2571–87.PubMedCrossRef
171.
Yang R, Shen S, Gong C, Wang X, Luo F, Luo F, et al. Bispecific antibody PD-L1 x CD3 boosts the anti-Tumor potency of the expanded Vγ2Vδ2 T cells. Front Immunol. 2021;12:654080.PubMedPubMedCentralCrossRef
172.
173.
174.
Hwang HJ, Lee JJ, Kang SH, Suh JK, Choi ES, Jang S, et al. The BTLA and PD-1 signaling pathways independently regulate the proliferation and cytotoxicity of human peripheral blood γδ T cells. Immun Inflamm Dis. 2021;9:274–87.PubMedCrossRef
175.
Tani-Ichi S, Wagatsuma K, Hara T, Cui G, Abe S, Miyachi H, et al. Innate-like CD27+CD45RBhigh γδ T cells require TCR signaling for homeostasis in peripheral lymphoid organs. J Immunol. 2020;204:2671–84.PubMedCrossRef
176.
177.
178.
179.
Yang Q, Liu X, Liu Q, Guan Z, Luo J, Cao G, et al. Roles of mTORC1 and mTORC2 in controlling γδ T1 and γδ T17 differentiation and function. Cell Death Differ. 2020;27:2248–62.PubMedPubMedCentralCrossRef
180.
181.
Schofield L, Ioannidis LJ, Karl S, Robinson LJ, Tan QY, Poole DP, et al. Synergistic effect of IL-12 and IL-18 induces TIM3 regulation of γδ T cell function and decreases the risk of clinical malaria in children living in Papua New Guinea. BMC Med. 2017;15:114.PubMedPubMedCentralCrossRef
182.
Tirier SM, Mallm J-P, Steiger S, Poos AM, Awwad MHS, Giesen N, et al. Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics. Nat Commun. 2021;12:6960.PubMedPubMedCentralCrossRef
183.
184.
185.
André P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, et al. Anti-NKG2A mAb Is a Checkpoint inhibitor that promotes anti-tumor Immunity by unleashing both T and NK cells. Cell. 2018;175:1731–1743.e13.PubMedPubMedCentralCrossRef
186.
187.
Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, et al. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014;211:781–90.PubMedPubMedCentralCrossRef
188.
van Hall T, André P, Horowitz A, Ruan DF, Borst L, Zerbib R, et al. Monalizumab: inhibiting the novel immune checkpoint NKG2A. J Immunother Cancer. 2019;7:263.PubMedPubMedCentralCrossRef
189.
Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009;206:3015–29.PubMedPubMedCentralCrossRef
190.
191.
Preillon J, Cuende J, Rabolli V, Garnero L, Mercier M, Wald N, et al. Restoration of T-cell effector function, depletion of Tregs, and direct killing of Tumor cells: The multiple mechanisms of action of a-TIGIT antagonist antibodies. Mol Cancer Ther. 2021;20:121–31.PubMedCrossRef
192.
193.
Zhou C, Lin A, Cao M, Ding W, Mou W, Guo N, et al. Activation of the DDR pathway leads to the Down-regulation of the TGFβ pathway and a better response to ICIs in patients with metastatic urothelial carcinoma. Front Immunol. 2021;12:634741.PubMedPubMedCentralCrossRef
194.
195.
196.
Turiello R, Capone M, Morretta E, Monti MC, Madonna G, Azzaro R, et al. Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents. J Immunother Cancer. 2022;10:e004043.PubMedPubMedCentralCrossRef
197.
Lu J-C, Zhang P-F, Huang X-Y, Guo X-J, Gao C, Zeng H-Y, et al. Amplification of spatially isolated adenosine pathway by tumor-macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma. J Hematol Oncol. 2021;14:200.PubMedPubMedCentralCrossRef
198.
Li C, Phoon YP, Karlinsey K, Tian YF, Thapaliya S, Thongkum A, et al. A high OXPHOS CD8 T cell subset is predictive of immunotherapy resistance in melanoma patients. J Exp Med. 2022;219:e20202084.PubMedCrossRef
199.
200.
Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016;7:10501.PubMedPubMedCentralCrossRef
201.
202.
203.
Imai Y, Ayithan N, Xuesong W, Yuan Y, Wang L, Hwang ST. Cutting edge: PD-1 regulates Imiquimod-induced Psoriasiform dermatitis through inhibition of IL-17A expression by innate γδ-low T cells. J Immunol. 2015;195:421–5.PubMedCrossRef
204.
Kadekar D, Agerholm R, Viñals MT, Rizk J, Bekiaris V. The immune checkpoint receptor associated phosphatases SHP-1 and SHP-2 are not required for γδT17 cell development, activation, or skin inflammation. Eur J Immunol. 2020;50:873–9.PubMedCrossRef
205.
Li N, Wenwen X, Yuan Y, Ayithan N, Imai Y, Xuesong W, et al. Immune-checkpoint protein VISTA critically regulates the IL-23/IL-17 inflammatory axis. Sci Rep. 2017;7:1485.PubMedPubMedCentralCrossRef
206.
Edwards SC, Hedley A, Hoevenaar WHM, Wiesheu R, Glauner T, Kilbey A, et al. PD-1 and TIM-3 differentially regulate subsets of mouse IL-17A-producing γδ T cells. J Exp Med. 2023;220:e20211431.PubMedCrossRef
207.
208.
209.
Choi J, Medikonda R, Saleh L, Kim T, Pant A, Srivastava S, et al. Combination checkpoint therapy with anti-PD-1 and anti-BTLA results in a synergistic therapeutic effect against murine glioblastoma. Oncoimmunology. 2021;10:1956142.PubMedPubMedCentralCrossRef
210.
Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with Immune Checkpoint blockade. N Engl J Med. 2018;378:158–68.PubMedCrossRef
211.
Sullivan RJ, Weber JS. Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. Nat Rev Drug Discov. 2022;21:495–508.PubMedCrossRef
212.
Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chávez A, Keegan N, Khamashta MA, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6:38.PubMedPubMedCentralCrossRef
213.
Tarhini AA, Zahoor H, Lin Y, Malhotra U, Sander C, Butterfield LH, et al. Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J Immunother Cancer. 2015;3:39.PubMedPubMedCentralCrossRef
214.
215.
Eggesbø LM, Risnes LF, Neumann RS, Lundin KEA, Christophersen A, Sollid LM. Single-cell TCR sequencing of gut intraepithelial γδ T cells reveals a vast and diverse repertoire in celiac disease. Mucosal Immunol. 2020;13:313–21.PubMedCrossRef
216.
Badran YR, Shih A, Leet D, Mooradian MJ, Coromilas A, Chen J, et al. Immune checkpoint inhibitor-associated celiac disease. J Immunother Cancer. 2020;8:e000958.PubMedPubMedCentralCrossRef
217.
Cheng M, Qian L, Shen G, Bian G, Xu T, Xu W, et al. Microbiota modulate tumoral immune surveillance in lung through a γδT17 immune cell-dependent mechanism. Cancer Res. 2014;74:4030–41.PubMedCrossRef
218.
219.
Barisa M, Kramer AM, Majani Y, Moulding D, Saraiva L, Bajaj-Elliott M, et al. E. coli promotes human Vγ9Vδ2 T cell transition from cytokine-producing bactericidal effectors to professional phagocytic killers in a TCR-dependent manner. Sci Rep. 2017;7:2805.PubMedPubMedCentralCrossRef
220.
Benakis C, Brea D, Caballero S, Faraco G, Moore J, Murphy M, et al. Commensal microbiota affects ischemic stroke outcome by regulating intestinal γδ T cells. Nat Med. 2016;22:516–23.PubMedPubMedCentralCrossRef
221.
Li F, Hao X, Chen Y, Bai L, Gao X, Lian Z, et al. The microbiota maintain homeostasis of liver-resident γδT-17 cells in a lipid antigen/CD1d-dependent manner. Nat Commun. 2017;7:13839.PubMedCrossRef
222.
223.
Herrmann T, Fichtner AS, Karunakaran MM. An update on the molecular basis of Phosphoantigen recognition by Vγ9Vδ2 T cells. Cells. 2020;9:E1433.CrossRef
224.
Mu X, Xiang Z, Xu Y, He J, Lu J, Chen Y, et al. Glucose metabolism controls human γδ T-cell-mediated tumor immunosurveillance in diabetes. Cell Mol Immunol. 2022;19:944–56.PubMedCrossRef
225.
Lopes N, McIntyre C, Martin S, Raverdeau M, Sumaria N, Kohlgruber AC, et al. Distinct metabolic programs established in the thymus control effector functions of γδ T cell subsets in tumor microenvironments. Nat Immunol. 2021;22:179–92.PubMedPubMedCentralCrossRef
226.
Kim M, Min YK, Jang J, Park H, Lee S, Lee CH. Single-cell RNA sequencing reveals distinct cellular factors for response to immunotherapy targeting CD73 and PD-1 in colorectal cancer. J Immunother Cancer. 2021;9:e002503.PubMedPubMedCentralCrossRef
227.
Taromi S, Firat E, Simonis A, Braun LM, Apostolova P, Elze M, et al. Enhanced AC133-specific CAR T cell therapy induces durable remissions in mice with metastatic small cell lung cancer. Cancer Lett. 2022;538:215697.PubMedCrossRef
228.
Laumont CM, Wouters MCA, Smazynski J, Gierc NS, Chavez EA, Chong LC, et al. Single-cell profiles and prognostic impact of Tumor-infiltrating lymphocytes Coexpressing CD39, CD103, and PD-1 in ovarian Cancer. Clin Cancer Res. 2021;27:4089–100.PubMedCrossRef
229.
Zhang T, Liu H, Jiao L, Zhang Z, He J, Li L, et al. Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL. J Immunother Cancer. 2022;10:e004114.PubMedPubMedCentralCrossRef
230.
Leem G, Park J, Jeon M, Kim E-S, Kim SW, Lee YJ, et al. 4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39+ CD8 T cells from primary and metastatic sites of epithelial ovarian cancers. J Immunother Cancer. 2020;8:e001650.PubMedPubMedCentralCrossRef
231.
Wang Y, Zhang H, Liu C, Wang Z, Wu W, Zhang N, et al. Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts. J Hematol Oncol. 2022;15:111.PubMedPubMedCentralCrossRef
232.
Agrati C, Cimini E, Sacchi A, Bordoni V, Gioia C, Casetti R, et al. Activated V gamma 9V delta 2 T cells trigger granulocyte functions via MCP-2 release. J Immunol. 2009;182:522–9.PubMedCrossRef
233.
Devilder M-C, Maillet S, Bouyge-Moreau I, Donnadieu E, Bonneville M, Scotet E. Potentiation of antigen-stimulated V gamma 9V delta 2 T cell cytokine production by immature dendritic cells (DC) and reciprocal effect on DC maturation. J Immunol. 2006;176:1386–93.PubMedCrossRef
234.
235.
Lee H, Jeong S, Shin E-C. Significance of bystander T cell activation in microbial infection. Nat Immunol. 2022;23:13–22.PubMedCrossRef
236.
237.
Meier SL, Satpathy AT, Wells DK. Bystander T cells in cancer immunology and therapy. Nat Cancer. 2022;3:143–55.PubMedCrossRef
238.
Rozenbaum M, Meir A, Aharony Y, Itzhaki O, Schachter J, Bank I, et al. Gamma-Delta CAR-T cells show CAR-directed and independent activity against leukemia. Front Immunol. 2020;11:1347.PubMedPubMedCentralCrossRef
239.
Ye X, Deng X, Wen J, Li Y, Zhang M, Cai Z, et al. Folate receptor-alpha targeted 7x19 CAR-γδT suppressed triple-negative breast cancer xenograft model in mice. J Oncol. 2022;2022:2112898.PubMedPubMedCentralCrossRef
240.
Capsomidis A, Benthall G, Van Acker HH, Fisher J, Kramer AM, Abeln Z, et al. Chimeric antigen receptor-engineered human Gamma Delta T cells: enhanced Cytotoxicity with retention of cross presentation. Mol Ther. 2018;26:354–65.PubMedCrossRef
241.
Rotolo R, Leuci V, Donini C, Cykowska A, Gammaitoni L, Medico G, et al. CAR-based strategies beyond T lymphocytes: integrative opportunities for Cancer adoptive immunotherapy. Int J Mol Sci. 2019;20:2839.PubMedPubMedCentralCrossRef
242.
Fisher J, Sharma R, Don DW, Barisa M, Hurtado MO, Abramowski P, et al. Engineering γδT cells limits tonic signaling associated with chimeric antigen receptors. Sci Signal. 2019;12:eaax1872.PubMedPubMedCentralCrossRef
243.
Harrer DC, Simon B, Fujii S-I, Shimizu K, Uslu U, Schuler G, et al. RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma. BMC Cancer. 2017;17:551.PubMedPubMedCentralCrossRef
244.
Harrer DC, Dörrie J, Schaft N. Chimeric antigen receptors in different Cell types: New vehicles join the race. Hum Gene Ther. 2018;29:547–58.PubMedCrossRef
245.
Jin C, Ma J, Ramachandran M, Yu D, Essand M. CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers. Nat Biomed Eng. 2022;6:830–41.PubMedPubMedCentralCrossRef
246.
Ferry GM, Agbuduwe C, Forrester M, Dunlop S, Chester K, Fisher J, et al. A simple and robust single-step method for CAR-Vδ1 γδT Cell expansion and transduction for Cancer immunotherapy. Front Immunol. 2022;13:863155.PubMedPubMedCentralCrossRef
247.
248.
Thedrez A, Harly C, Morice A, Salot S, Bonneville M, Scotet E. IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy. J Immunol. 2009;182:3423–31.PubMedCrossRef
249.
Zumwalde NA, Sharma A, Xuequn X, Ma S, Schneider CL, Romero-Masters JC, et al. Adoptively transferred Vγ9Vδ2 T cells show potent antitumor effects in a preclinical B cell lymphomagenesis model. JCI Insight. 2017;2 American Society for Clinical Investigation. Available from: https://​insight.​jci.​org/​articles/​view/​93179. Cited 2022 Jul 17.
250.
Metadata
Title
Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment
Authors
Zhifei Gao
Yifeng Bai
Anqi Lin
Aimin Jiang
Chaozheng Zhou
Quan Cheng
Zaoqu Liu
Xin Chen
Jian Zhang
Peng Luo
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2023
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/s12943-023-01722-0

Other articles of this Issue 1/2023

Molecular Cancer 1/2023 Go to the issue

Research

TGF-β signaling promotes cervical cancer metastasis via CDR1as

Correction

Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy

Correspondence

REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial

Review

Clinical application and detection techniques of liquid biopsy in gastric cancer

Correction

Correction: CircNFIB inhibits tumor growth and metastasis through suppressing MEK1/ERK signaling in intrahepatic cholangiocarcinoma

Correspondence

Significant CircRNAs in liver cancer stem cell exosomes: mediator of malignant propagation in liver cancer?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits